UniProtKB/Swiss-Prot Q9UBP0 : Variant p.Asp441Val
Spastin
Gene: SPAST
Feedback ?
Variant information
Variant position:
441
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Aspartate (D) to Valine (V) at position 441 (D441V, p.Asp441Val).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from medium size and acidic (D) to medium size and hydrophobic (V)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In SPG4.
Any additional useful information about the variant.
Sequence information
Variant position:
441
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
616
The length of the canonical sequence.
Location on the sequence:
KLVRALFAVARELQPSIIFI
D EVDSLLCERREGEHDASRRL
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human KLVRALFAVARELQPSIIFID EVDSLLCERREGEHDASRRL
Mouse KLVRALFAVARELQPSIIFID EVDSLLCERREGEHDASRRL
Rat KLVRALFAVARELQPSIIFID EVDSLLCERREGEHDASRRL
Pig KLVRALFAVARELQPSIIFID EVDSLLRERREGEHDASRRL
Bovine KLVRALFAVARELQPSIIFID EVDSLLCERREGEHDASRRL
Chicken KLVRALFAVARELQPSIIFID EVDSLLCERREGEHDASRRL
Xenopus laevis KLVRALFSVARELQPSIIFID EVDSLLCERREGEHDASRRL
Xenopus tropicalis KLVRALFSVARELQPSIIFID EVDSLLCERREGEHDASRRL
Zebrafish KLVRALFAVARELQPSIIFID EIDSLLCERREGEHDASRRL
Caenorhabditis elegans KTIRGLFQIARNAQPSIIFID EIDSILCERSEKDAEVSRRM
Drosophila KLVRALFAVARHMQPSIIFID EVDSLLSERSSSEHEASRRL
Slime mold KLVRALFAVATHFQPSIIFID EIDSLLTERSSNESEASRRL
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 616
Spastin
Topological domain
78 – 616
Cytoplasmic
Region
228 – 616
Sufficient for microtubule severing
Mutagenesis
442 – 442
E -> Q. Abrogates ATP hydrolysis, abolishes microtubule severing, stabilizes the homohexameric form, and promotes microtubule binding and redistribution from the endosome to microtubules.
Mutagenesis
448 – 448
C -> AG. Abolishes ATPase activity.
Mutagenesis
448 – 448
C -> S. Does not affect ATPase activity.
Mutagenesis
451 – 451
R -> G. Abrogates binding to the tail of alpha-tubulin and beta-3-tubulin, impairs ATPase activity and abolishes microtubule severing.
Mutagenesis
457 – 457
A -> E. Abrogates binding to the tail of alpha-tubulin and beta-3-tubulin and abolishes microtubule severing.
Beta strand
435 – 442
Literature citations
Spastin mutation screening in Chinese patients with pure hereditary spastic paraplegia.
Wei Q.Q.; Chen Y.; Zheng Z.Z.; Chen X.; Huang R.; Yang Y.; Burgunder J.; Shang H.F.;
Parkinsonism Relat. Disord. 20:845-849(2014)
Cited for: VARIANTS SPG4 PRO-363; LEU-399; VAL-441 AND ARG-595;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.